UK markets close in 2 hours 39 minutes

Akari Therapeutics, Plc (AKTX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.52000.0000 (0.00%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 12.04M
Enterprise value 12.04M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.07
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.51

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-59.57%
S&P500 52-week change 328.04%
52-week high 35.5000
52-week low 31.0780
50-day moving average 31.5358
200-day moving average 32.7957

Share statistics

Avg vol (3-month) 317.99k
Avg vol (10-day) 315.27k
Shares outstanding 57.92M
Implied shares outstanding 65.06M
Float 89.56B
% held by insiders 12,017.91%
% held by institutions 12.28%
Shares short (30 Apr 2024) 42.21k
Short ratio (30 Apr 2024) 40.12
Short % of float (30 Apr 2024) 40.05%
Short % of shares outstanding (30 Apr 2024) 40.03%
Shares short (prior month 28 Mar 2024) 410.52k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 317 Aug 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-210.95%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -18.18M
Net income avi to common (ttm)-16.57M
Diluted EPS (ttm)-2.0500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.31M
Total cash per share (mrq)0
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)0.44
Book value per share (mrq)-0.44

Cash flow statement

Operating cash flow (ttm)-15.6M
Levered free cash flow (ttm)-9.76M